Potential of AAV vectors in the treatment of metabolic disease
Open Access
- 10 April 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 15 (11), 831-839
- https://doi.org/10.1038/gt.2008.64
Abstract
No abstract availableKeywords
This publication has 89 references indexed in Scilit:
- Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicityBrain Research, 2008
- Adenovirus-Mediated Gene Delivery Rescues a Neonatal Lethal Murine Model of mut0 Methylmalonic AcidemiaHuman Gene Therapy, 2008
- Enhanced Response to Enzyme Replacement Therapy in Pompe Disease after the Induction of Immune ToleranceAmerican Journal of Human Genetics, 2007
- Metabolic phenotype of methylmalonic acidemia in mice and humans: the role of skeletal muscleBMC Medical Genetics, 2007
- Long-Term Rescue of a Lethal Inherited Disease by Adeno-Associated Virus–Mediated Gene Transfer in a Mouse Model of Molybdenum-Cofactor DeficiencyAmerican Journal of Human Genetics, 2007
- PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pahenu2 miceBrain Research, 2007
- Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extentCardiovascular Diabetology, 2007
- Enhanced Efficacy of an AAV Vector Encoding Chimeric, Highly Secreted Acid α-Glucosidase in Glycogen Storage Disease Type IIMolecular Therapy, 2006
- Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8Molecular Therapy, 2006
- Four New Mutations in the Ornithine Transcarbamylase GeneBiochemical Medicine and Metabolic Biology, 1993